Ligand Pharmaceuticals Inc. (NASDAQ:LGND) Director Jason Aryeh sold 18,479 shares of the firm’s stock in a transaction dated Friday, November 25th. The shares were sold at an average price of $107.31, for a total transaction of $1,982,981.49. Following the transaction, the director now directly owns 58,959 shares in the company, valued at $6,326,890.29. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Jason Aryeh also recently made the following trade(s):

  • On Friday, November 18th, Jason Aryeh sold 6,330 shares of Ligand Pharmaceuticals stock. The shares were sold at an average price of $105.28, for a total transaction of $666,422.40.

Shares of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) traded down 0.06% during trading on Friday, reaching $106.77. 144,372 shares of the company traded hands. The company’s 50-day moving average price is $98.66 and its 200-day moving average price is $112.47. The company has a market capitalization of $2.23 billion, a P/E ratio of 305.93 and a beta of 1.43. Ligand Pharmaceuticals Inc. has a 52 week low of $82.06 and a 52 week high of $139.79.

Ligand Pharmaceuticals (NASDAQ:LGND) last announced its quarterly earnings results on Thursday, November 3rd. The biotechnology company reported $0.62 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.59 by $0.03. The company had revenue of $21.62 million for the quarter, compared to analysts’ expectations of $23.64 million. Ligand Pharmaceuticals had a net margin of 8.51% and a return on equity of 9.98%. Ligand Pharmaceuticals’s revenue was up 22.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.57 EPS. Equities research analysts forecast that Ligand Pharmaceuticals Inc. will post $3.40 EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

TRADEMARK VIOLATION NOTICE: “Ligand Pharmaceuticals Inc. (LGND) Director Jason Aryeh Sells 18,479 Shares” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another website, it was illegally stolen and reposted in violation of international trademark and copyright law. The legal version of this news story can be read at https://www.thecerbatgem.com/2016/11/25/ligand-pharmaceuticals-inc-lgnd-director-jason-aryeh-sells-18479-shares.html.

A number of analysts recently issued reports on LGND shares. CJS Securities decreased their price objective on shares of Ligand Pharmaceuticals from $130.00 to $125.00 and set an “outperform” rating for the company in a report on Wednesday, September 28th. Roth Capital set a $154.00 price objective on shares of Ligand Pharmaceuticals and gave the stock a “buy” rating in a report on Monday. TheStreet downgraded shares of Ligand Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, October 7th. Craig Hallum raised their price objective on shares of Ligand Pharmaceuticals from $150.00 to $160.00 in a report on Wednesday, October 5th. Finally, Zacks Investment Research upgraded shares of Ligand Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, November 9th. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Ligand Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $139.70.

Institutional investors have recently made changes to their positions in the company. Meridian Investment Counsel Inc. boosted its position in Ligand Pharmaceuticals by 1.0% in the second quarter. Meridian Investment Counsel Inc. now owns 2,920 shares of the biotechnology company’s stock valued at $348,000 after buying an additional 30 shares in the last quarter. D.A. Davidson & CO. boosted its position in Ligand Pharmaceuticals by 2.4% in the third quarter. D.A. Davidson & CO. now owns 1,722 shares of the biotechnology company’s stock valued at $174,000 after buying an additional 40 shares in the last quarter. Hanseatic Management Services Inc. boosted its position in Ligand Pharmaceuticals by 0.8% in the second quarter. Hanseatic Management Services Inc. now owns 7,819 shares of the biotechnology company’s stock valued at $933,000 after buying an additional 60 shares in the last quarter. Isthmus Partners LLC boosted its position in Ligand Pharmaceuticals by 0.9% in the third quarter. Isthmus Partners LLC now owns 6,807 shares of the biotechnology company’s stock valued at $651,000 after buying an additional 61 shares in the last quarter. Finally, Independent Portfolio Consultants Inc. boosted its position in Ligand Pharmaceuticals by 4.3% in the third quarter. Independent Portfolio Consultants Inc. now owns 1,575 shares of the biotechnology company’s stock valued at $161,000 after buying an additional 65 shares in the last quarter.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals.

5 Day Chart for NASDAQ:LGND

Receive News & Stock Ratings for Ligand Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.